Diffuse hair loss in an adult female: Approach to diagnosis and management

Indian Journal of Dermatology, Venereology and Leprology

Volumn 75, Issue 1, 2009, Pages 20-28

  Shrivastava, Shyam ^a  

^a Dr Baba Sahib Ambedkar Hospital   (India)

Author keywords

Chronic telogen effluvium; Diffuse alopecia; Female pattern hair loss; Telogen effluvium

Indexed keywords

ANTIANDROGEN; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYPROTERONE ACETATE; ETHINYLESTRADIOL; ETRETIN; ETRETINATE; FERROUS SULFATE; FLUTAMIDE; HEPARIN; LIOTHYRONINE; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; PLACEBO; RETINOID DERIVATIVE; SPIRONOLACTONE; THYROTROPIN;

ALOPECIA; BIRTH; BLOOD CELL COUNT; CHRONIC TELOGEN EFFLUVIUM; CLINICAL FEATURE; FEMALE PATTERN HAIR LOSS; FERRITIN BLOOD LEVEL; HAIR TRANSPLANTATION; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERTRICHOSIS; IRON DEFICIENCY; PROGNOSIS; REVIEW; SKIN ALLERGY; SKIN IRRITATION; TELOGEN EFFLUVIUM; THYROID DISEASE; URINALYSIS;

ADULT; ALOPECIA; ANEMIA, IRON-DEFICIENCY; DISEASE MANAGEMENT; FEMALE; HAIR; HAIR DISEASES; HAIR PREPARATIONS; HUMANS; THYROID DISEASES;

EID: 59249089031     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.45215     Document Type: Review

References (61)

1. Kligman AM. Pathologic dynamics of hair loss.1. Telogen effluvium. Arch Dermatol 1961;83:175-98.
2. Headington JT. Telogen effluvium: New concepts and views. Arch Dermatol 1993;129:356-63.
3. Feidler VC, Hafeez A. Diffuse alopecia: telogen hair loss. In: Olsen EA, editor.
4. nd ed. New york: McGraw- Hill; 2003. p. 301-21.
5. Bordin MB. Drug related alopecia. Dermatol clin 1987;5:571-9.
6. Shapiro J, Wiseman M, Lui H. Practical management of hair loss. Can Fam Physician 2000;46:1469-77.
7. Thiedke CC. Alopecia in Women. Am Fam Physician 2003;67:1007-14.
8. Chong AH, Wade M, Sinclarer RD. The hair pull test and hair pluck for analysis of hair abnormalities. Modern Medicine of Australia 1999;42:105-18.
9. Shapiro J, Lui H. Common hair loss disorders. In: Hordiwnsky MK, Sawaya ME, Scher RK, editors. Atlas of Hairs and Nails. Churchil Livingston; 2000. P. 91-103.
10. Saitoh M, UzukaM, Sakamoto M. Human hair cycle. J Invest Dermatol 1970;54:65-81.
11. Dhurat R. Phototrichogram. Indian J Dermatol Venereol Leprol 2006;72:242-4.
12. Hoffman R. Trichoscan: Combining epiluminiscence microscopy with digital image analyses for measurement of hair growth in vivo. Eur J Dermatol 2001;11:362-8.
13. Tosti A, Piraccini BM. Telogen effluvium. In: Tosti A, Piraccini BM, editors Diagnosis and Treatment of Hair Disorders. UK: Taylor and France; 2006. p. 57-61.
14. Ross EK, VincenziC, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol 2006;55:799-806.
15. de Lacharriere O, Deloche C, Miscicali C, Piraccini BM, Vincenzi C, Bastein P, et al. Hair diameter diversity: A clinical sign reflecting the follicular miniaturization. Arch Dermatol 2001;137:641-6.
16. Lacarruba F, Dall.Oglio F, Rita Nasca M, Micali G. Videodermoscopy enhances diagnostic capability in some form of hair loss. Am J Clin Dermatol 2004;5:205-8.
17. Whiting D, Howsden F. Colour Atlas of Differential Diagnosis of Hair Loss. Cedar Grove, NJ: Carnfield Publishing; 1996.
18. Sperling L. Evaluation of hair loss. Current Problems in Dermatology 1996;8:2-30.
19. th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 483-5.
20. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006;54:824-44.
21. Ross EK, Shapiro J. Management of hair loss. Dermatol clin 2005;23:227-43.
22. Chartier MB, Hoss DM, Grant-kels JM. Approach to the adult female patient with diffuse non scaring alopecia. J Am Acad Dermatol 2002;47:809-19.
23. Sinclair R. Diffuse hair loss. Int J Dermatol 1999;38:8-18.
24. Pringle T. The relationship between thyroxin, estradiol and postnatal alopecia, with relevance to women's health in general. Med Hypothesis 2000;55:44-9.
25. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al. The effect of finestride, a 5a- reductase inhibitor, on scalp skin testosterone and dihydro-testosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-6.
26. Sawaya MF, Price VH. Different levels of 5a- reductase type I and type II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300.
27. th ed. McGraw-hill publishing: New York; 2003. p. 643-4.
28. Futterweit MD, Dunaif A, Yeh HC, Kingslay P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988;19:831-6.
29. Pitaway DE. Neoplastic causes of hyperandrogenism. Infertility and Reproductive Medicine Clinics of North America 1991;2:479-94.
30. Whiting DA. Scalp biopsy as a diagnostic and prognostic tool in androgenetic alopecia. Dermatololgic Therapy 1998;3:24-33.
31. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male patterned androgenetic alopecia. J Am Acad Dermatol 1993; 28:755-63.
32. Whiting DA. Chromic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996;35:899-906.
33. Rebora A, Guarrera M, Baldari M, Vechhio F. Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient. Arch Dermatol 2005;141:1243-5.
34. Sinclair R, Jolley D, Mallari R, Maqee J. The reliability of horizontally sectioned scalp biopsies in the diagnosis of chronic diffuse telogen hair loss in women. J Am Acad Dermatol 2004;51:189-99.
35. Kantor J, Kessier LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Inv Dermatol 2003;121:985-8.
36. Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002;147:982-4.
37. Aydingoz IE, Ferhanoglu B, Guney O. Does tissue iron status have a role in female alopecia? J Eur Acad Derm Venereol 1999;13:65-7.
38. Rushton DH. Management of hair loss in women. Dermatol Clin 1993;11:47-53.
39. White MI, Currie J, Williams MP. A study of tissue iron status of patients with alopecia areata. Br J Dermatol 1994;130:261-3.
40. Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002;27:396-404.
41. Boffa MJ, Wood P, Griffiths CE. Iron status of patients with alopecia areata. Br J Dermatol 1995;132:662-4.
42. Rushton DH, Ramsay ID, James KC, Norris MJ, Gillkis JJ. Biomedical and trichological characterization of diffuse alopecia in women. Br J Dermatol 1990;123:187-97.
43. Olsen EA. Iron deficiency and hair loss: The jury is still out. J Am Acad Dermatol 2006;54:903-06.
44. Goddard AF, Mclntyre AS, Scott BB. Guidelines for the management of iron deficiency anemia. British Society of Gastroenterology. Gut 2000;46:IV1-5.
45. Sinclair R. Chronic telogen effluvium: A study of 5 patients over 7 years. J Am Acad Dermatol 2005;52:512-6.
46. Olsen EA, Messenger AG, Shapiro J, Bergfled WF, Hordinsky MK, Robert JL, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52:301-11.
47. De Villez R, Jacobs JP, Szpunar CA, Warner ML. Androgenetic alopecia in the female: treatment wiith 2% minoxidil solution. Arch Dermatol 1994;130:303-7.
48. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004;50:541-53.
49. Vexian P, Chaspoux C, Boudon P, Fiet J, Jaunanique C, Hardy N, et al. Effects of minoxidil 2% vs. Cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12 month randomized trial. Br J Dermatol 2002;146:992-9.
50. Dawber RP, Rundegren J. Hypertrichosis in females applying minoxidil topical solution and in normal controls. J Eur Acad Dermatol Venereol 2003;17:271-5.
51. Shapiro J. Safety of topical minoxidil: A one year prospective, observational study. J Cutan Med Surg 2003;7:322-9.
52. Diamanti-Kandarakis E. Current aspect of antiandrogens therapy in women. Current Pharmaceutical Design 1999;5:707-23.
53. Adamopoulos DA, Karamerlzanis M, Ncckopoulou S, Gregoriou A. A beneficial effect of spironolactone on androgenetic alopecia. Clin Endocrinol (Oxf) 1997;47:759-60.
54. Rushton DH. Quantitative assessment of spironolactone treatment in women with diffuse androgen dependent alopecia. J Soc Cosmet Chem 1991;42:317.
55. Shapiro J. Hair loss: Principles of diagnosis and management of alopecia. London: Martin Dunitz; 2002. p.83-121.
56. Carmina E, Lobo RA. Treatment of hyperandrogenetic alopecia in women. Fertil Steril 2003;79:91-5.
57. Peereboom-Wniya JD, van der Willigen AH, van Jost T, Stolz E. The effects of cyproterone acetate on hair roots and hair shaft diameters in androgenetic alopecia in females. Acta Derm Venereol 1989;69:395-8.
58. Barth H, Cherry CA, Wofnazowska F. Cyproterone acetate for severe hirsutism: Results of a double blind dose- ranging study. Clin Endocrinol (Oxf) 1991;35:5-10.
59. Shum KW, Cullen DR, Messanger AG. Hair loss in women with hyperandrogenism: four eases responding to finastride. J Am Acad Dermatol 2002;47:733-9.
60. Price VH, Roberts JL, Hordinskym, Olsen EA, Savin R, Bergfed W, et al. Lack of efficiency of finestride in post-menopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43:768-76.
61. Thai KE, Sinclair RD. Finestride for female androgenetic alopecia. Br J Dermatol 2002;147:812-3.